biosimilars – Our Curious Amalgam

Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

Posted 12 months ago Tagged analysis antitrust biologics biosimilars competition economics generics intellectual property law litigation market payment pharmaceutical settlement

Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]

Adrian van den Hoven, Director General, Medicines for Europe

#114 What Are the Generic and Biosimilar Industries Worried About? Current Competition Law Issues Impacting the Sector.

Posted 2 years ago Tagged biosimilars comfort letter COVID denigration divisional patents European Commission generics patent linkage pharmaceuticals

Generics and biosimilars are an important part of the pharmaceutical landscape in Europe. What are […]